NCT05103254 Bempedoic Acid Pregnancy Surveillance Program
| NCT ID | NCT05103254 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Esperion Therapeutics, Inc. |
| Condition | Pregnancy |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2021-09-01 |
| Primary Completion | 2032-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2021-09-01 with a primary completion date of 2032-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bempedoic acid pregnancy surveillance program
Eligibility Criteria
Inclusion Criteria: Exposure to at least 1 dose of bempedoic acid or bempedoic acid/ezetimibe FCDP at any time during pregnancy (from first day of last menstrual period \[LMP\] to pregnancy outcome Exclusion Criteria:
Contact & Investigator
Christine Broestl, MS
STUDY DIRECTOR
Esperion Therapuetics
Frequently Asked Questions
Who can join the NCT05103254 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05103254 currently recruiting?
Yes, NCT05103254 is actively recruiting participants. Contact the research team at Bempedoic.Acid.PSP@ppd.com for enrollment information.
Where is the NCT05103254 trial being conducted?
This trial is being conducted at Morrisville, United States.
Who is sponsoring the NCT05103254 clinical trial?
NCT05103254 is sponsored by Esperion Therapeutics, Inc.. The principal investigator is Christine Broestl, MS at Esperion Therapuetics. The trial plans to enroll 20 participants.